Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

Autor: José Luis Arredondo-García, Kriengsak Limkittikul, Carmen Deseda, Maria Rosario Capeding, Doris Maribel Rivera-Medina, Melanie Saville, Reynaldo Dietze, Betzana Zambrano, Fanouillere K, Eric Plennevaux, Muhammad Ismail Hi, Tram Anh Wartel, Jackson N, Forrat R, Sophia Gailhardou, Alain Bouckenooghe, Carina Frago, Margarita Cortés, Danaya Chansinghakul, Fernando Noriega, Tran Hn, Humberto Reynales, Hadinegoro, Chotpitayasunondh T

Publikováno v: New England Journal of Medicine. 373:1195-1206

BACKGROUND A candidate tetravalent dengue vaccine is being assessed in three clinical trials involving more than 35,000 children between the ages of 2 and 16 years in Asian– Pacific and Latin American countries. We report the results of long-term f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26b86ca2be81217525f12d9655c842e6
https://doi.org/10.1056/nejmoa1506223

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Autor: Hadinegoro SR; From Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta (S.R.H.); Instituto Nacional de Pediatria, Mexico City (J.L.A.-G.); Research Institute for Tropical Medicine, Muntinlupa City, the Philippines (M.R.C.); Caribbean Travel Medicine Clinic, San Juan, Puerto Rico (C.D.); Queen Sirikit National Institute of Child Health (T.C.), Faculty of Tropical Medicine, Mahidol University (K.L.), and Sanofi Pasteur (D.C.) - all in Bangkok, Thailand; Nucleo de Doencas Infecciosas, Universidade Federal do Espirito Santo, Vitoria, ES, Brazil (R.D.); Hospital Kuala Lumpur, Kuala Lumpur, Malaysia (H.I.H.M.I.); Centro de Atencion e Investigacion Medica SAS-CAIMED (H.R.), and Sanofi Pasteur (M.C.) - both in Bogota, Colombia; Organizacion para el Desarrollo y la Investigacion Salud en Honduras (ODIS), Tegucigalpa (D.M.R.-M.); Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City, Vietnam (H.N.T.); Sanofi Pasteur, Singapore, Singapore (A.B., C.F., T.A.W.); Sanofi R&D, Chilly-Mazarin (K.F.), Marcy l'Etoile (R.F., E.P.), and Lyon (S.G., N.J., M.S.) - all in France; Sanofi Pasteur, Swiftwater, PA (F.N.); and Sanofi Pasteur, Montevideo, Uruguay (B.Z.)., Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortés M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M

Publikováno v: The New England journal of medicine [N Engl J Med] 2015 Sep 24; Vol. 373 (13), pp. 1195-206. Date of Electronic Publication: 2015 Jul 27.

Characteristics of children hospitalized for pandemic (H1N1) 2009, Malaysia.

Autor: Muhammad Ismail HI; Hospital Kuala Lumpur, Kuala Lumpur, Malaysia., Tan KK, Lee YL, Pau WS, Razali KA, Mohamed T, Adnan T, Subramaniam P, Hanif J

Publikováno v: Emerging infectious diseases [Emerg Infect Dis] 2011 Apr; Vol. 17 (4), pp. 708-10.